Cellmid Ltd - New Signed Distribution Agreements
Cellmid Ltd (ASX:CDY)

New Signed Distribution Agreements

Published Oct 02, 2019

What happened?


Europe Expansion:

Cellmid has entered into a supply agreement for its évolis® Professional anti-aging hair care and hair loss products with leading European beauty retailer, Douglas GmbH.

China Expansion:

Cellmid has signed an exclusive distribution agreement with Aeon International for évolis® Professional to be sold in the Chinese cross-border e-commerce market.

Global Growth:

These new channels and partners are expected to continue to drive consumer health revenue growth in Europe and China, in addition to existing geographies.

CEO's summary

Maria Halasz CEO of Cellmid Ltd has provided a statement.
Maria Halasz
Maria Halasz
CEO, Cellmid Ltd

“We are delighted to announce these new distribution and sales channels with quality partners around the world. As we continue to work with our new and existing partners worldwide, it strengthens our confidence in the robust, omnichannel model and growth profile of our consumer health division. We look forward to expanding our product sales in FY2020 and beyond as a result.”

Analysts thoughts

SmallCapInsider from Mawson Graham provides perspective on this recent announcement.
SmallCapInsider
Written by SmallCapInsider
Published Oct 02, 2019

We believe that this agreement with Douglas GmbH is evidence that Cellmid is continuing to execute on its omni-channel distribution strategy. As new territories continue to unlock we believe that this will likely lead to increased sales over time, and in turn, help push the company's Advangen subsidiary toward break-even in FY19/20 and beyond over the coming years.

Download Announcement

View this announcement as well as our full profile on the company.

Comments

Share your thoughts about this announcement...

Similar articles
Independent test results for the Wondfo SARS-COV-2 Test
What's happened? Cellmid Limited (ASX:CDY) has announced that a validation study has been completed for the Wondfo SARS-...
1 year ago
Cellmid share placement raises $6m to fund SARS-V-2 diagnostic test roll out
What's happened? Cellmid Limited (ASX:CDY) has raised $6 million (before costs) via a share placement from institutional...
1 year ago
Cellmid enter into supply agreement for COVID-19 rapid diagnostic test
What's happened? Cellmid Ltd (ASX: CDY, “Cellmid”) have announced that it has entered into a supply agreement for a COVI...
1 year ago
Around the web
Reporting Season Round Up: The good times roll on for COVID beneficiary stocks
In 2021 many COVID beneficiary stocks actually dropped following their financial results, as investo...
via stockhead.com.au
Why are ASX-listed stocks PBH, HNG, DCC on investors’ radar today?
Highlights PointsBet has been appointed as Austin FC’s Exclusive Sportsbook Partner through an e...
via kalkinemedia.com
ASX Health Stocks: M&A winds blow as API gets an upgraded offer from Wesfarmers, jumps 15pc
The ASX 200 health stocks index (XHJ) has lifted by 0.46% at the time of writing, compared to the br...
via stockhead.com.au
Powered by  
  • Company
    Cellmid Ltd
  • Website
  • Sector
    Biotechnology
  • Industry
    Biotechnology
  • Code
    ASX:CDY
  • Socials
View Cellmid Ltd's Profile

How do I invest?

Considering investing in Cellmid Ltd?
Here's how to get started.
Low Cost Brokerage ASX Cheapest ASX Trading Platform
  1. 1

    Create account

    Open an account with an online broker of your choice. If you do not have an existing broker, consider Mawson Graham's A$9.50 flat fee platform.

    Sign up now »
  2. 2

    Search for ASX:CDY

    On your online investment platform search for the stock ticker code ASX:CDY to bring up the company's shares.

  3. 3

    Buy shares

    Place your order however you wish. If you need advice on buying or selling, you should seek the assistance of a full service financial adviser experienced in small cap equities.

Up